NCT04421378: A trial that was reported late by Karyopharm Therapeutics Inc
This trial has reported, although it was 22 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04421378 |
|---|---|
| Title | A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 8, 2020 |
| Completion date | July 3, 2023 |
| Required reporting date | July 2, 2024, midnight |
| Actual reporting date | July 25, 2024 |
| Date last checked at ClinicalTrials.gov | May 29, 2026 |
| Days late | 22 |